Measuring Variant-Specific Neutralizing Antibody Profiles after Bivalent SARS-CoV-2 Vaccinations Using a Multivariant Surrogate Virus Neutralization Microarray
Open Access
Abstract
The capability of antibodies to neutralize different SARS-CoV-2 variants varies among individuals depending on the previous exposure to wild-type or Omicron-specific immunogens by mono- or bivalent vaccinations or infections. Such profiles of neutralizing antibodies (nAbs) usually have to be assessed via laborious live-virus neutralization tests (NTs). We therefore analyzed whether a novel multivariant surrogate-virus neutralization test (sVNT) (adapted from a commercial microarray) that quantifies the antibody-mediated inhibition between the receptor angiotensin-converting enzyme 2 (ACE2) and variant-specific receptor-binding domains (RBDs) can assess the neutralizing activity against the SARS-CoV-2 wild-type, and Delta Omicron BA.1, BA.2, and BA.5 subvariants after a booster with Omicron-adapted bivalent vaccines in a manner similar to live-virus NTs. Indeed, by using the live-virus NTs as a reference, we found a significant correlation between the variant-specific NT titers and levels of ACE2-RBD binding inhibition (p < 0.0001, r ≤ 0.78 respectively). Furthermore, the sVNTs identified higher inhibition values against BA.5 and BA.1 in individuals vaccinated with Omicron-adapted vaccines than in those with monovalent wild-type vaccines. Our data thus demonstrate the ability of sVNTs to detect variant-specific nAbs following a booster with bivalent vaccines.Keywords
All Related Versions
This publication has 23 references indexed in Scilit:
- Omicron BA.1 breakthrough infection drives cross-variant neutralization and memory B cell formation against conserved epitopesScience Immunology, 2022
- Effectiveness of 2, 3, and 4 COVID-19 mRNA Vaccine Doses Among Immunocompetent Adults During Periods when SARS-CoV-2 Omicron BA.1 and BA.2/BA.2.12.1 Sublineages Predominated — VISION Network, 10 States, December 2021–June 2022MMWR. Morbidity and Mortality Weekly Report, 2022
- Different Neutralization Profiles After Primary SARS-CoV-2 Omicron BA.1 and BA.2 InfectionsFrontiers in Immunology, 2022
- Neutralization Escape by SARS-CoV-2 Omicron Subvariants BA.2.12.1, BA.4, and BA.5New England Journal of Medicine, 2022
- BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infectionNature, 2022
- Neutralization Profile after Recovery from SARS-CoV-2 Omicron InfectionNew England Journal of Medicine, 2022
- Efficacy of a Fourth Dose of Covid-19 mRNA Vaccine against OmicronNew England Journal of Medicine, 2022
- mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variantNature Medicine, 2022
- SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responsesCell, 2022
- Measurement in Medicine: The Analysis of Method Comparison StudiesJournal of the Royal Statistical Society: Series D (The Statistician), 1983